Altoida

Altoida, Inc is creating a new gold standard in brain health with Precision Neurology. Their innovative approach combines novel digital biomarkers (dBM) with immersive augmented reality (AR) and powerful artificial intelligence (AI). The result is a validated device and platform built on more than twenty years of cutting-edge scientific research. Altoida’s products are backed by peer-reviewed publications and multinational clinical trials, and are built by their expert team of scientists, clinicians and engineers.

https://altoida.com/

Team Member
more about
Therese Liechtenstein
Investment Director
Latest News Entry
2022/03/30
Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform

Altoida, Inc. raised an additional $14 million for its Series A round with new and existing investors. The investment was co-led by M Ventures and Whitecap Venture Partners

2021/10/18
Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University

Research collaboration will identify new opportunities in the fight against Alzheimer’s and further validate the predictive diagnostic capabilities of Altoida’s software medical device.

2021/09/03
Altoida Unveils New Brand Identity with Reimagined Logo and Website

Refreshed brand identity reflects Altoida’s emphasis on data and humanity, and will support the company’s growth as the world leader in Precision Neurology

2021/08/05
Altoida Awarded FDA Breakthrough Designation for Development of World’s First Precision Neurology Device for Prediction of Alzheimer's Disease

Breakthrough Designation will advance the development of industry’s first predictive diagnostic device for conversion to Alzheimer’s disease, backed by two decades of global clinical studies

2019/06/01
Altoida raises $6.3m Series A to Predict Alzheimer’s Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality

New digital biomarkers company secures $6.3 MM in venture capital to detect Alzheimer’s disease 6-10 years prior to onset of Mild Cognitive Impairment (MCI) symptoms - with up to 94% accuracy

all related news
all portfolio news